USPTO serial 79447238
NANOBIOTIX EXPANDING LIFE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- BLAZICH, JOAN MICHELE
- Law office
- TMO LAW OFFICE 122
What this means
Status 680 means the examining attorney approved your mark for publication in the USPTO Official Gazette. Publication for opposition usually follows within weeks, opening a 30-day window for third parties to oppose. Watch for publication (status 686) and monitor the 30-day opposition window.
Need help with NANOBIOTIX EXPANDING LIFE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Vivian Ortiz-Ponce
Vivian Ortiz-Ponce Perez Guerrero LLCPO BOX 9024163San Juan, PR 00969United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Chemical preparations for medical use for the diagnosis and treatment of cancerous tumors; Radiosensitizing pharmaceutical agents for making cancerous tissues more sensitive to radiation therapy; Pharmaceutical preparations for the targeted delivery of active ingredients for treating cancer; Contrast agents for use in MRI, X-ray computed tomography, ultrasound, X-ray and angiography and nuclear imaging; Preparations for medical use, namely, for modifying the bioavailability of therapeutic agents; Preparations for medical use for modifying liver functions; Pharmaceutical preparation based on nanomaterials for the delivery of therapeutic agents for treating cancer; Products for medical use, namely, pharmaceuticals for the treatment of brain diseases and disorders; pharmaceutical preparations for the diagnosis and treatment of brain diseases and disorders; Preparations for medical use particularly for the treatment of Parkinson's disease, Alzheimer's disease, epilepsy and all types of neurological and neuropsychiatric diseases and disorders; pharmaceutical preparations for the diagnosis and treatment of neurological disorders and diseases using deep brain stimulation, electrical transcranial stimulation, transcranial direct-current stimulation, transcranial magnetic stimulation, any form of electromagnetic light, magnetic field, electric field stimulation, radio frequency or ultrasound stimulation; Diagnostic products, namely, diagnostic reagents for medical use; Drugs for medical use, namely, pharmaceutical preparations for treating cancer | ACTIVE | — |
| 010 | Medical devices using nanoparticles for therapeutic or diagnostic purposes, namely, for treating tumors; Medical instruments for delivering or activating therapeutic substances for treating cancerous tumors; Medical devices for combination with ionizing radiation for diagnosis and therapy of cancerous tumors; surgical and medical devices and instruments for deep brain stimulation, electrical transcranial stimulation, transcranial direct-current stimulation, transcranial magnetic stimulation, any form of electromagnetic light, magnetic field, electric field stimulation, radio frequency or ultrasound stimulation; medical apparatus containing electrodes, electroencephalograph, micro-electrode arrays for the recording of electrical brain activity; medical apparatus for neuronal modeling | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 5, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 11, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 11, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 11, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 10, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 10, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 10, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Sep 10, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Aug 13, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 24, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 24, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 7, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 5, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 3, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 3, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 3, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 2, 2026 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |